Hartung Daniel M, Ahmed Sharia M, Middleton Luke, Van Otterloo Joshua, Zhang Kun, Keast Shellie, Kim Hyunjee, Johnston Kirbee, Deyo Richard A
Oregon State University/Oregon Health & Science University, Portland, OR, USA.
Oregon Public Health Division, Portland, OR, USA.
Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1053-1060. doi: 10.1002/pds.4254. Epub 2017 Jul 19.
Out-of-pocket payment for prescription opioids is believed to be an indicator of abuse or diversion, but few studies describe its epidemiology. Prescription drug monitoring programs (PDMPs) collect controlled substance prescription fill data regardless of payment source and thus can be used to study this phenomenon.
To estimate the frequency and characteristics of prescription fills for opioids that are likely paid out-of-pocket by individuals in the Oregon Medicaid program.
Cross-sectional analysis using Oregon Medicaid administrative claims and PDMP data (2012 to 2013).
Continuously enrolled nondually eligible Medicaid beneficiaries who could be linked to the PDMP with two opioid fills covered by Oregon Medicaid.
Patient characteristics and fill characteristics for opioid fills that lacked a Medicaid pharmacy claim. Fill characteristics included opioid name, type, and association with indicators of high-risk opioid use.
A total of 33 592 Medicaid beneficiaries filled a total of 555 103 opioid prescriptions. Of these opioid fills, 74 953 (13.5%) could not be matched to a Medicaid claim. Hydromorphone (30%), fentanyl (18%), and methadone (15%) were the most likely to lack a matching claim. The 3 largest predictors for missing claims were opioid fills that overlapped with other opioids (adjusted odds ratio [aOR] 1.37; 95% confidence interval [CI], 1.34-1.4), long-acting opioids (aOR 1.52; 95% CI, 1.47-1.57), and fills at multiple pharmacies (aOR 1.45; 95% CI, 1.39-1.52).
Prescription opioid fills that were likely paid out-of-pocket were common and associated with several known indicators of high-risk opioid use.
自付处方阿片类药物费用被认为是滥用或转移的一个指标,但很少有研究描述其流行病学情况。处方药监测项目(PDMPs)收集受控物质处方配药数据,无论支付来源如何,因此可用于研究这一现象。
估计俄勒冈医疗补助计划中可能由个人自付费用的阿片类药物处方配药的频率和特征。
使用俄勒冈医疗补助管理索赔和PDMP数据(2012年至2013年)进行横断面分析。
连续登记的非双重资格医疗补助受益人,他们可与PDMP关联,且有两次由俄勒冈医疗补助覆盖的阿片类药物配药。
缺乏医疗补助药房索赔的阿片类药物配药的患者特征和配药特征。配药特征包括阿片类药物名称、类型以及与高风险阿片类药物使用指标的关联。
共有33592名医疗补助受益人开具了总计555103份阿片类药物处方。在这些阿片类药物配药中,74953份(13.5%)无法与医疗补助索赔匹配。氢吗啡酮(30%)、芬太尼(18%)和美沙酮(15%)最有可能缺乏匹配索赔。缺失索赔的3个最大预测因素是与其他阿片类药物重叠的阿片类药物配药(调整优势比[aOR]1.37;95%置信区间[CI],1.34 - 1.4)、长效阿片类药物(aOR 1.52;95%CI,1.47 - 1.57)以及在多个药房的配药(aOR 1.45;95%CI,1.39 - 1.52)。
可能自付费用的处方阿片类药物配药很常见,且与几个已知的高风险阿片类药物使用指标相关。